The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
Recruiting · NCT05778253 · Registry updated 2023-03-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC | squamous cell lung carcinoma | Recruiting | Not stated | 2023-03-21 | NCT05778253 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Second Xiangya Hospital of Central South University | 95 |
| Shanghai OrigiMed Co., Ltd. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China | Changsha | China | 2 |